01 July 2005 : Original article
Hemochromatosis-causing mutations C282Y and H63D are not risk factors for atherothrombotic cerebral infarction.
Helena Hruskovicová, Tomaz Milanez, Jan Kobal, Karmen Peterlin Potisk, Danijel Petrovic, Borut PeterlinMed Sci Monit 2005; 11(7): BR248-252 :: ID: 16977
Abstract
Background: It has been suggested that iron metabolism may be involvedin the pathogenesis of atherothrombotic cerebral infarction (ACI). The C282Y and H63D mutations in thehemochromatosis (HFE) gene are associated with increased serum iron levels and net iron accumulation.The aim of this study was to test the hypothesis that the C282Y and H63D mutations in the HFE gene arerisk factors for ACI in a Slovene population. Material/Methods: The C282Y and H63D HFE gene mutationswere tested in 96 Caucasian patients who had suffered an acute cerebral infarction, later confirmed asACI, and 115 control subjects. Genotypes were determined by electrophoresis of the DNA digestion productsfrom RsaI (C282Y) and MboI (H63D). Results: We failed to demonstrate that the C282Y and H63D mutationswere risk factors for ACI in Caucasians. The percentage of C282Y and H63D genotypes (dominant model)in ACI-cases (C282Y: 7.3%, n=7; H63D: 28.1%, n=27) did not differ significantly (P=0.9 and P=0.7 respectively)from that of the controls (C282Y: 7.0%, n=8; H63D: 26.1%, n=30). Logistic regression analysis revealedthat arterial hypertension, diabetes, and cigarette smoking are independent risk factors for ACI, whereasthe C282Y and H63D HFE gene mutations are not. Conclusions: We provided evidence that the C282Y and H63DHFE gene mutations were not risk factors for ACI in this Slovene population.
Keywords: Intracranial Arteriosclerosis - genetics, Intracranial Thrombosis - complications, Intracranial Thrombosis - genetics, Cerebral Infarction - genetics, Diabetes Complications, Hemochromatosis - genetics, Hypertension - complications, Intracranial Arteriosclerosis - genetics, Intracranial Thrombosis - genetics, Mutation, Risk Factors, Slovenia, Smoking - adverse effects
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952